Novartis AG (NVS)
141.86
+0.32
(+0.23%)
USD |
NYSE |
Jan 12, 16:00
141.86
0.00 (0.00%)
After-Hours: 19:53
Novartis Research and Development Expense (Quarterly): 2.857B for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Amgen, Inc. | 1.90B |
| AstraZeneca PLC | 3.530B |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Avidity Biosciences, Inc. | 154.95M |